# BIOLOGICA LLC: Preclinical development of novel dual EZH2-BRD4 inhibitor for EZH2-mutant lymphoma

**Lab Budget Score:** 40/100

| Field | Value |
|---|---|
| Organization | BIOLOGICA LLC |
| Location | CHARLOTTE, NC |
| Project | Preclinical development of novel dual EZH2-BRD4 inhibitor for EZH2-mutant lymphoma |
| Project number | 1R43CA314643-01 |
| Mechanism | R43 |
| Institute | National Cancer Institute |
| Award | $385,056 |
| Awarded | 2026-09-17 |
| Project period | 2026-09-22 to 2027-08-31 |
| UEI | YLL9C3R1E9K5 |

## Why this score
- Award of $385,056.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11407995). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.